Sentence examples for another trial reported from inspiring English sources

Another trial reported last year of the T-cell therapy on the liquid tumours of people with advanced multiple myeloma – a cancer of plasma cells in the bone marrow and blood – produced "persistent and prolonged" effects in 16 out of 20 patients, with 14 showing a near-complete or complete response.

While there was a double-blind, placebo-controlled clinical study on oral supplements containing collagen published in October 2014 that showed promising results among elderly women and another trial reported that same year on Pure Gold Collagen supplements, Weiser still believes these products "do not have a proven biologic mechanism of action".

Another trial reported an increase of disease activity for the combination of atorvastatin with interferon-β [11] whereas one subsequent trial did not find such an adverse effect [12].

Another trial reported a significant decrease in HbA1c of 0.3% in the intervention group compared with the control group [ 42].

Another trial reported that therapy with docetaxel was completely ineffective in oesophageal adenocarcinoma (Heath et al, 2002).

Another trial reported that 49% of patients treated with cetuximab and concurrent radiotherapy developed a grade III or IV radiation dermatitis [ 18].

Five trials (Table 3) included outcomes related to TA activity with one trial showing a statistically significant difference between experimental and comparison groups for changes to TA thickness [ 61] and another trial reporting a significant difference in the ratio of TA to Rectus Abdominus (RA) activity during double leg raise.

In trial reports authors could report evidence that a treatment's efficacy was superior to placebo if 1 of 12 outcome measures showed a significant effect of treatment, whereas in another trial report in the same journal, authors could suggest that the same treatment was not efficacious if 2 or 3 of the outcomes showed significant efficacy over placebo.

Another docetaxel/capecitabine trial reported a response rate of 46% and median survival of 15.8 months [ 21].

Another recent trial reported negative results in reducing cognitive decline in older adults with normal cognition or with mild cognitive impairment [ 5].

Another Italian trial reported a trend toward improved overall survival for anthracycline over CMF therapy for women with HER2-positive disease (hazard ratio 0.85, 95% confidence interval [CI] 0.27 2.71) but not for those with HER2-negative disease (hazard ratio 1.64, 95% CI 0.85 3.14) (#133).